Cipla has obtained approvals to launch Remdesivir below model title Cipremi (Representational)
New Delhi:
With pharmaceutical corporations launching generic variations of Remdesivir and Favipiravir for COVID-19 therapy, medical consultants on Monday stated it was a “positive development” within the battle towards the pandemic, however cautioned towards relating to the antiviral medication as “game changers”.
Glenmark Pharmaceuticals has launched the antiviral drug Favipiravir, below the model title FabiFlu, for the therapy of delicate to average COVID-19 circumstances, whereas Cipla and Hetero have obtained approvals from the Drug Controller General of India (DCGI) to launch Remdesivir below the model names Cipremi and Covifor respectively.
Cipla Ltd on Sunday introduced the launch of Cipremi.
Dr Sanjay Rai, Professor on the Centre for Community Medicine, AIIMS Delhi, stated until date no efficient therapy or vaccine to fight coronavirus has been discovered.
“Till date we don’t have evidence that a particular drug is effective, so we cannot call any drug game changer till then. With their launch, it will only be clear in the future how effective they will be. Whether they can play a supportive role in COVID-19 treatment is also not yet known,” he instructed PTI.
Dr Vikas Maurya, Director, Department of Pulmonology and Sleep Disorders, Fortis Hospital, Shalimar Bagh, stated medication like Remdesivir and Favipiravir had been “no game changers” as they had been used for different ailments and have now been discovered helpful ultimately in treating COVID-19 sufferers.
“It is not as if all those taking these drugs will recover,” he instructed PTI.
It has been discovered that they assist scale back viral load however will not be recreation changers, Maurya stated.
“But yes, it is a positive development as it is better to have something in hand than nothing. There is also a psychological impact that something is being given which could have some benefit,” he stated.
Dr Rommel Tickoo, Associate Director, Internal Medicine, Max Healthcare, additionally echoed Maurya’s views.
Whatever research which were completed on these medication are very restricted so that they can’t be known as “game changers”, however their launch is a constructive improvement as it’s higher to have one thing than nothing, he stated.
“On both the drugs we have limited data, whatever evidence we have is mostly anecdotal. There is no specific treatment that we have and we cannot wait for all the trials to be over as many lives will be lost. So that is why emergency restricted use is being approved,” he instructed PTI.
“It is difficult for us to categorically state the efficacy of the drugs, they do have the potential, but we need more data,” he stated.
Noted city-based lung surgeon Dr Arvind Kumar stated he doesn’t imagine that any of those antiviral medication like Remdisiver or Favipiravir shall be recreation changers.
“If at all “recreation changer” can be used, it is for dexamethasone which has shown a significant reduction in mortality and is available cheaply,” stated Kumar, who works on the Sir Ganga Ram Hospital right here.
Dr Avi Kumar, Consultant, Pulmonologist, Fortis Escort Heart Institute, stated medication similar to Favipiravir and Remdisiver “cannot be called game changers” as they’re used as a supportive therapy.
“When given early, they can benefit patients but there is no guarantee that the patient will improve or not,” he stated.
“It is definitely a positive development that we will be using antivirals, but it is not a game changer as that term can be used for something which you give and the patient recovers,” Kumar instructed PTI.
Drug agency Hetero had on Sunday stated it has obtained approval from regulator DCGI to launch investigational antiviral drug Remdesivir for the therapy of COVID-19.
The drug shall be obtainable in 100 mg vials (injectable) which must be administered intravenously in a hospital setting below the supervision of a healthcare practitioner, it stated.
Asked in regards to the value of the drug, Hetero Group of Companies MD Vamsi Krishna Bandi instructed PTI will probably be within the vary of Rs 5,000-6,000 per dose.
The drug has been granted approval by DCGI for the therapy of suspected or laboratory-confirmed circumstances of COVID-19 in adults and kids, hospitalised with extreme signs of the illness, the corporate stated.
Cipla has additionally stated that it has been granted regulatory approval by the DCGI for restricted emergency use within the nation as a part of the accelerated approval course of contemplating the pressing and unmet medical want.
Commenting on the launch, Cipla Ltd MD and Global CEO Umang Vohra stated, “Cipla appreciates the strong partnership with Gilead to bring Remdesivir to patients in India. We have been deeply invested in exploring all possible avenues to save millions of lives impacted by COVID-19 pandemic, and this launch is a significant milestone in that direction”.
In May, home pharma companies Hetero, Cipla and Jubilant Life Sciences had entered into non-exclusive licensing agreements with drug main Gilead Sciences Inc for manufacturing and distribution of Remdesivir.
Glenmark Pharmaceuticals final week stated it has launched antiviral drug Favipiravir, below the model title FabiFlu, for the therapy of sufferers with delicate to average COVID-19 at a value of about Rs 103 per pill.
FabiFlu is the primary oral Favipiravir-approved treatment in India for the therapy of COVID-19, it stated in an announcement.
(Except for the headline, this story has not been edited by NDTV employees and is printed from a syndicated feed.)